Krop IE - Search Results

1

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.

Barroso-Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido-Castro AC, Hughes M, Bychkovsky B, Umeton R, Files JL, Lindeman NI, MacConaill LE, Hodi FS, Krop IE, Dillon D, Winer EP, Wagle N, Lin NU, Mittendorf EA, Van Allen EM, Tolaney SM. Barroso-Sousa R, et al. Among authors: krop ie. Clin Cancer Res. 2020 Jun 1;26(11):2565-2572. doi: 10.1158/1078-0432.CCR-19-3507. Epub 2020 Feb 4. Clin Cancer Res. 2020. PMID: 32019858 Free PMC article.

2

A SAGE (serial analysis of gene expression) view of breast tumor progression.

Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, Riggins G, Polyak K. Porter DA, et al. Among authors: krop ie. Cancer Res. 2001 Aug 1;61(15):5697-702. Cancer Res. 2001. PMID: 11479200

3

Ovarian suppression for breast cancer: an effective treatment in search of a home.

Krop IE, Winer EP. Krop IE, et al. J Clin Oncol. 2005 Sep 1;23(25):5869-72. doi: 10.1200/JCO.2005.06.002. Epub 2005 Aug 8. J Clin Oncol. 2005. PMID: 16087947 No abstract available.

4

A putative role for psoriasin in breast tumor progression.

Krop I, März A, Carlsson H, Li X, Bloushtain-Qimron N, Hu M, Gelman R, Sabel MS, Schnitt S, Ramaswamy S, Kleer CG, Enerbäck C, Polyak K. Krop I, et al. Cancer Res. 2005 Dec 15;65(24):11326-34. doi: 10.1158/0008-5472.CAN-05-1523. Cancer Res. 2005. PMID: 16357139

5

Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?

Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M. Segara D, et al. Among authors: krop ie. J Surg Oncol. 2007 Nov 1;96(6):474-80. doi: 10.1002/jso.20856. J Surg Oncol. 2007. PMID: 17640031 Clinical Trial.

6

Ten years of HER2-directed therapy: still questions after all these years.

Krop IE, Winer EP. Krop IE, et al. Breast Cancer Res Treat. 2009 Jan;113(2):207-9. doi: 10.1007/s10549-008-0041-2. Epub 2008 May 8. Breast Cancer Res Treat. 2009. PMID: 18463974 No abstract available.

7

Mechanisms of trastuzumab resistance in breast cancer.

Tolaney SM, Krop IE. Tolaney SM, et al. Among authors: krop ie. Anticancer Agents Med Chem. 2009 Mar;9(3):348-55. doi: 10.2174/1871520610909030348. Anticancer Agents Med Chem. 2009. PMID: 19275526 Review.

8

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA. Krop IE, et al. J Clin Oncol. 2010 Jun 1;28(16):2698-704. doi: 10.1200/JCO.2009.26.2071. Epub 2010 Apr 26. J Clin Oncol. 2010. PMID: 20421541 Clinical Trial.

9

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.

Mayer EL, Krop IE. Mayer EL, et al. Among authors: krop ie. Clin Cancer Res. 2010 Jul 15;16(14):3526-32. doi: 10.1158/1078-0432.CCR-09-1834. Clin Cancer Res. 2010. PMID: 20634194 Review.

10

GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays.

Li A, Liu Z, Lezon-Geyda K, Sarkar S, Lannin D, Schulz V, Krop I, Winer E, Harris L, Tuck D. Li A, et al. Nucleic Acids Res. 2011 Jul;39(12):4928-41. doi: 10.1093/nar/gkr014. Epub 2011 Mar 11. Nucleic Acids Res. 2011. PMID: 21398628 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

228 results

Search Page